Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

Hadji, Peyman; Aapro, Matti S.; Body, Jean-Jacques; Gnant, Michael; Brandi, Maria Luisa; Reginster, Jean Yves; Zillikens, M. Carola; Glüer, Claus-C.; de Villiers, Tobie; Baber, Rod; Roodman, G. David; Cooper, Cyrus; Langdahl, Bente; Palacios, Santiago; Kanis, John; Al-Daghri, Nasser; Nogues, Xavier; Eriksen, Erik Fink; Kurth, Andreas; Rizzoli, René; Coleman, Robert E.

doi:10.1016/j.jbo.2017.03.001

Scientific article

English

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

Published inJournal of bone oncology, vol. 7, p. 1-12

Publication date2017

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Génétique des ostéoporoses (544)

Citation (ISO format)

HADJI, Peyman et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. In: Journal of bone oncology, 2017, vol. 7, p. 1–12. doi: 10.1016/j.jbo.2017.03.001